Favorite this paper
How to cite this paper?
Abstract

Introduction-Parkinson's disease (PD) is characterized by the pathologic aggregation of α-synuclein, which induces endoplasmic reticulum (ER) stress and activates the unfolded protein response (UPR), ultimately leading to the death of dopaminergic neurons. Objectives-This study investigated whether drugs known to mitigate protein aggregation in prion disease models would attenuate the stress response and cell death in PD models. Methods-Flunarizine and ten of its structural analogues, previously identified through a drug repositioning approach to reduce the aggregation of PrPSc prion protein, were evaluated in a Chinese hamster ovary (CHO-K1) cell model. Results/Discussion-First, UPR was induced in CHO-K1 cells using tunicamycin, revealing that several of these drugs conferred protection and also reduced the expression of the UPR marker CHOP. Subsequently, we tested these anti-prion drugs in PD relevant cellular models. Neuronally-differentiated PC12 cells were employed, and all 11 drugs exhibited protective effect. Finally, human dopaminergic neurons (LUHMES cells) were exposed to 1-methyl-4-phenylpyridinium (MPP+), a compound commonly used to induce parkinsonian-like pathology. In this model, all 11 drugs demonstrated cytoprotective properties and attenuated UPR. Notably, several compounds - benzydamine, duloxetine, flunarizine, metixene and triflupromazine – protected LUHMES cells from MPP+-induced ER stress at nanomolar concentrations. Conclusion-These findings provide the proof of concept that drugs approved for other indications, may be repurposed to ameliorate PD and related pathologies linked to ER stress.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, F-29200 Brest, France
  • 2 Univ Brest, Inserm, IMT-A, UMR 1101, LaTIM, School of Medicine, 22 avenue Camille Desmoulins, F-29200 Brest; Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, F-29200 Brest, France
  • 3 Department of Biological Sciences, School of Life Sciences and Environment, Royal Holloway University of London, Egham TW20 0EX, UK
  • 4 Universität Konstanz Department of Biology, Fach 657 D-78457 Konstanz, Germany
  • 5 Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, 105 boulevard de l’Hôpital, 75013 Paris, France
  • 6 Laboratoire d’Innovation Thérapeutique, LIT, UMR7200, IMS MEDALIS, Faculty of Pharmacy, CNRS, Université de Strasbourg, 74 route du Rhin - CS 60024 - Illkirch F-67400, France
Track
  • Therapeutic approaches for prion and prion-like diseases
Keywords
Anti-prion drugs
Parkinson’s disease
drug repurposing
endoplasmic reticulum stress
LUHMES cells differentiated into dopaminergic-like neurons